Clinical efficacy of combination of oxaliplatin and vascular intervention in treatment of advanced cervical cancer and related prognostic factors

被引：2
作者：
Huang, Xinlong [1 ]
Yang, Haiyan [2 ]
Su, Zhenqing [1 ]
Wang, Junsong [1 ]
Zhang, Jianxun [1 ]
Zhang, Xinqin [2 ]
机构：
[1] First Peoples Hosp Wenling, Dept Vasc Tumor Intervent, Wenling 317500, Peoples R China
[2] First Peoples Hosp Wenling, Dept Gynecol, Wenling 317500, Peoples R China
来源：
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH | 2022年 / 21卷 / 03期
关键词：
Oxaliplatin; Vascular intervention; Advanced cervical cancer; Prognosis; CELLS;
D O I：
10.4314/tjpr.v21i3.26
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Purpose: To investigate the therapeutic effect of combination of oxaliplatin and vascular intervention in patients with advanced cervical cancer (ACC), and its influence on the prognosis of patients. Methods: One hundred ACC patients were selected and equally assigned to control (oxaliplatin) and combination or study (oxaliplatin plus vascular intervention) groups. The patients in control group received oxaliplatin, while those in study group were treated with oxaliplatin combined with vascular intervention. Clinical efficacy, levels of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2 (VEGFR-2), fibroblast growth factor-2 (FGF-2), BFGF and platelet-derived growth factor (PDGF) before and after therapy, and survival rate at 3, 6, 12 and 18 months after therapy were determined compared between the two groups. The prognostic factors were analyzed with logistic factor analysis. Results: The clinical efficacy and survival rate at 3, 6, 12 and 18 months after therapy in the combination group were higher when compared with those of the control group (p < 0.05). After therapy, the levels of VEGF, VEGFR-2, FGF-2, BFGF and PDGF were lower in the combination group than in control group. Age, short-term efficacy and basic diseases were identified as the influencing factors for the prognosis of patients with advanced cervical cancer (p < 0.05). Conclusion: The combination of oxaliplatin and vascular intervention significantly improved clinical treatment efficacy and survival rate in ACC patients. Age, short-term efficacy and basic diseases affected the prognosis of patients.
引用
收藏
页码：643 / 648
页数：6
相关论文
共 50 条
[11]   Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer [J].
Lan, Yan-qin ;
Kong, Ling-jun ;
Lin, Xiao-yan ;
Xu, Qian ;
Gao, Xin-yan ;
Wu, Ri-ping ;
Wang, Xin-li ;
Zhong, Dong-ta .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) :1007-1015
[12]   Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer [J].
Amarantidis, K. ;
Xenidis, N. ;
Chelis, L. ;
Chamalidou, E. ;
Dimopoulos, P. ;
Michailidis, P. ;
Tentes, A. ;
Deftereos, S. ;
Karanikas, M. ;
Karayiannakis, A. ;
Kakolyris, S. .
ONCOLOGY, 2011, 80 (5-6) :359-365
[13]   Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer [J].
Yan-qin Lan ;
Ling-jun Kong ;
Xiao-yan Lin ;
Qian Xu ;
Xin-yan Gao ;
Ri-ping Wu ;
Xin-li Wang ;
Dong-ta Zhong .
Cancer Chemotherapy and Pharmacology, 2018, 81 :1007-1015
[14]   Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients [J].
Bajetta, E ;
Beretta, E ;
Di Bartolomeo, M ;
Cortinovis, D ;
Ferrario, E ;
Dognini, G ;
Toffolatti, L ;
Buzzoni, R .
ONCOLOGY, 2004, 66 (02) :132-137
[15]   Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer [J].
Hu, Yu-xiong ;
Guo, Li-jing ;
Lin, Meng-qing ;
Lin, Qing-yu .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (04) :161-166
[16]   Retrospective Evaluation of the Efficacy of First-Line Treatment of Advanced Gastric Cancer With Docetaxel and Oxaliplatin [J].
Mao, Zhi-yuan ;
Guo, Xiao-chuan ;
Su, Dan ;
Wang, Li-jie ;
Zhang, Ting-ting ;
Bai, Li .
CANCER INVESTIGATION, 2015, 33 (01) :16-21
[17]   Survival rate and prognostic factors in advanced cervical cancer patients accompanied by renal impairment [J].
Rasjidi, Imam ;
Nuranna, Laila ;
Aziz, M. Farid ;
Andrijono, Andrijono ;
Purbadi, Sigit ;
Rochani, Rochani ;
Supriana, Nana ;
Dharmeizar, Dharmeizar ;
Sutrisna, Bambang .
MEDICAL JOURNAL OF INDONESIA, 2005, 14 (03) :173-178
[18]   siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy [J].
Shiri Aghbash, Parisa ;
Hemmat, Nima ;
Baradaran, Behzad ;
Bannazadeh Baghi, Hossein .
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
[19]   Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen [J].
Schüll, B ;
Kornek, GV ;
Schmid, K ;
Raderer, M ;
Ulrich-Pur, H ;
Fiebiger, W ;
Schneeweiss, B ;
Lenauer, A ;
Depisch, D ;
Scheithauer, W .
ONKOLOGIE, 2002, 25 (04) :358-362
[20]   Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer [J].
Xu, Rong ;
Ma, Nan ;
Wang, Fang ;
Ma, Lei ;
Chen, Rui ;
Chen, Ru ;
Kebinu, Mijiti ;
Ma, Lili ;
Han, Zhongcheng ;
Ayixiamu ;
Mayier, Mahemiti ;
Su, Pengcheng ;
Naman, Yiming ;
Jieensi, Haliyazimu ;
Yang, Haixuan ;
Adili, Abulizi ;
Aili, Saiding ;
Liu, Jiang .
ONCOTARGETS AND THERAPY, 2013, 6 :925-929
12345